JNJ-86974680

Phase 1Small molecule

Johnson & Johnson

JNJ-86974680 is one of 116 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Prostate CancerActive, not recruiting

Carcinoma, Non-Small-Cell LungRecruiting

Prostatic NeoplasmsRecruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

Carcinoma, Non-Small-Cell LungPhase 1

Recruiting

Prostatic NeoplasmsPhase 1

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

72 2

Lenvima

Eisai

Preclinical

6 3

Vizimpro

Pfizer

Preclinical

4 4

Gilotrif

Boehringer Ingelheim

Preclinical

12 5

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 6

JNJ-86974680

Johnson & Johnson

Phase 1

2 7

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 8

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Vidaza

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Prostatic Neoplasms

NCT07319871

Q2 2029

Phase 1Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06116786

Clinical

Trials by Indication[1]

Prostatic Neoplasms1 trial

A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07319871·40 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-Small Cell Lung Cancer

Recruiting·JJohnson & Johnson Enterprise Innovation Inc.·Phase 1·NCT06116786·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for JNJ-86974680. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-86974680 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-86974680. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Johnson & Johnson

JNJ-86974680

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2029

Trials by Indication[1]

Prostatic Neoplasms1 trial

Carcinoma, Non-Small-Cell Lung1 trial

References

Drug Info

Quick Facts

Related News